You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Mallinckrodt
Johnson and Johnson
Baxter
Express Scripts

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Trastuzumab; hyaluronidase-oysk - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for trastuzumab; hyaluronidase-oysk
Recent Litigation for trastuzumab; hyaluronidase-oysk

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all trastuzumab; hyaluronidase-oysk litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-01-08
2017-12-20

See all trastuzumab; hyaluronidase-oysk litigation

Patent Text Search: US Patents for trastuzumab; hyaluronidase-oysk

These patents were identified by searching patent claims

Supplementary Protection Certificates for trastuzumab; hyaluronidase-oysk

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000027 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021
C00150 Luxembourg   Start Trial PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
692 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
0130035 00163 Estonia   Start Trial PRODUCT NAME: TRASTUZUMABEMTANSIIN;REG NO/DATE: K(2013)8149 (LOPLIK) 19.11.2013
2016034 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
McKesson
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.